Plasma Fibroblast Growth Factor 23 as a Predictor for Fosinopril Therapeutic Efficacy in Pediatric Primary Hypertension

Plasma Fibroblast Growth Factor 23 as a Predictor for Fosinopril Therapeutic Efficacy in Pediatric Primary Hypertension

Background Plasma fibroblast growth factor 23 (FGF23) has been reported to be a predictive biomarker for therapeutic effectiveness of angiotensin‐converting enzyme inhibitors in heart failure. Higher plasma FGF23 levels have been shown in pediatric primary hypertension, but the predictive value of F...

Full description

Bibliographic Details
Main Authors: Yao Lin, Yaxi Cui, Yue Yuan, Lu Gao, Qirui Li, Xiaolan Huang, Yanyan Liu, Lin Shi
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
angiotensin‐converting enzyme inhibitors
effectiveness
fibroblast growth factor
hypertension
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.121.023182

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.121.023182

Similar Items